(Q45870268)

17 December 2017

title

Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). (English)

1 reference

17 December 2017

1 reference

Jourdier TM

1

1 reference

17 December 2017

Moste C

2

1 reference

17 December 2017

Bonnet MC

3

1 reference

17 December 2017

Delisle F

4

1 reference

17 December 2017

Tafani JP

5

1 reference

17 December 2017

Devauchelle P

6

1 reference

17 December 2017

Tartaglia J

7

1 reference

17 December 2017

Moingeon P

8

1 reference

17 December 2017

publication date

1 December 2003

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

26

1 reference

17 December 2017

page(s)

2126-2132

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302124

exact match

0 references

cites work

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Recombinant viruses as a tool for therapeutic vaccination against human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Immunisation with canarypox virus expressing rabies glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Therapeutic vaccines against melanoma and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Cancer modeling in the modern era: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

1 reference

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

7 January 2021

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302124

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302124

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017